Literature DB >> 15672866

Inostamycin suppresses vascular endothelial growth factor-stimulated growth and migration of human umbilical vein endothelial cells.

Yuh Baba1, Yasumasa Kato, Izumi Mochimatsu, Yoji Nagashima, Miki Kurihara, Toshiro Kawano, Takahide Taguchi, Ryu-Ichiro Hata, Mamoru Tsukuda.   

Abstract

Angiogenesis involves multiple steps including proliferation and migration of endothelial cells. In the present study, we determined the effect of inostamycin (an inhibitor of phosphatidylinositol synthesis) on vascular endothelial growth factor (VEGF)-induced proliferation and migration of human umbilical vein endothelial cells (HUVECs). Inostamycin significantly attenuated both VEGF-induced proliferation and migration of HUVECs. Inostamycin inhibited activation of mitogen-activated kinases (ERK and p38) and elevation of cyclin D1 induced by VEGF. These data suggest that inostamycin reduced both proliferation and migration of HUVECs by targeting ERK-cyclin D1 and p38, respectively.

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15672866     DOI： 10.1007/s10585-005-0041-0

Source DB:  PubMed          Journal:  Clin Exp Metastasis        ISSN： 0262-0898            Impact factor:   5.150


  35 in total

1.  Molecular marker expression in oral and oropharyngeal squamous cell carcinoma.

Authors:  B D Smith; G L Smith; D Carter; M P DiGiovanna; K M Kasowitz; C T Sasaki; B G Haffty
Journal:  Arch Otolaryngol Head Neck Surg       Date:  2001-07

2.  Induction of SPARC by VEGF in human vascular endothelial cells.

Authors:  Y Kato; J M Lewalle; Y Baba; M Tsukuda; N Sakai; M Baba; K Kobayashi; S Koshika; Y Nagashima; F Frankenne; A Noël; J M Foidart; R I Hata
Journal:  Biochem Biophys Res Commun       Date:  2001-09-21       Impact factor: 3.575

3.  Synergy between angiostatin and endostatin: inhibition of ovarian cancer growth.

Authors:  Y Yokoyama; M Dhanabal; A W Griffioen; V P Sukhatme; S Ramakrishnan
Journal:  Cancer Res       Date:  2000-04-15       Impact factor: 12.701

4.  Prognostic significance of vascular endothelial growth factor protein levels in oral and oropharyngeal squamous cell carcinoma.

Authors:  B D Smith; G L Smith; D Carter; C T Sasaki; B G Haffty
Journal:  J Clin Oncol       Date:  2000-05       Impact factor: 44.544

Review 5.  New paradigms for the treatment of cancer: the role of anti-angiogenesis agents.

Authors:  J M Cherrington; L M Strawn; L K Shawver
Journal:  Adv Cancer Res       Date:  2000       Impact factor: 6.242

6.  Human oral squamous cell carcinoma cell lines promote angiogenesis via expression of vascular endothelial growth factor and upregulation of KDR/flk-1 expression in endothelial cells.

Authors:  Y Michi; I Morita; T Amagasa; S Murota
Journal:  Oral Oncol       Date:  2000-01       Impact factor: 5.337

7.  Reduction of in vivo tumor growth by MMI-166, a selective matrix metalloproteinase inhibitor, through inhibition of tumor angiogenesis in squamous cell carcinoma cell lines of head and neck.

Authors:  Hideaki Katori; Yuh Baba; Yukari Imagawa; Goshi Nishimura; Yuumi Kagesato; Emi Takagi; Akiko Ishii; Shunsuke Yanoma; Ryuji Maekawa; Takayuki Yoshioka; Yoji Nagashima; Yasumasa Kato; Mamoru Tsukuda
Journal:  Cancer Lett       Date:  2002-04-25       Impact factor: 8.679

8.  Antimitogenic and proapoptotic activities of methylseleninic acid in vascular endothelial cells and associated effects on PI3K-AKT, ERK, JNK and p38 MAPK signaling.

Authors:  Z Wang; C Jiang; H Ganther; J Lü
Journal:  Cancer Res       Date:  2001-10-01       Impact factor: 12.701

9.  Transmembrane domain of Bcl-2 is required for inhibition of ceramide synthesis, but not cytochrome c release in the pathway of inostamycin-induced apoptosis.

Authors:  Makoto Kawatani; Madoka Uchi; Siro Simizu; Hiroyuki Osada; Masaya Imoto
Journal:  Exp Cell Res       Date:  2003-05-15       Impact factor: 3.905

10.  Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3'-kinase/Akt signal transduction pathway. Requirement for Flk-1/KDR activation.

Authors:  H P Gerber; A McMurtrey; J Kowalski; M Yan; B A Keyt; V Dixit; N Ferrara
Journal:  J Biol Chem       Date:  1998-11-13       Impact factor: 5.157
View more
  4 in total

1.  Present and Future of EGFR Inhibitors for Head and Neck Squamous Cell Cancer.

Authors:  Yuh Baba; Masato Fujii; Yutaka Tokumaru; Yasumasa Kato
Journal:  J Oncol       Date:  2012-03-26       Impact factor: 4.375

2.  Deguelin induces apoptosis by targeting both EGFR-Akt and IGF1R-Akt pathways in head and neck squamous cell cancer cell lines.

Authors:  Yuh Baba; Masato Fujii; Toyonobu Maeda; Atsuko Suzuki; Satoshi Yuzawa; Yasumasa Kato
Journal:  Biomed Res Int       Date:  2015-05-17       Impact factor: 3.411

3.  The anti-cancer compound Nordy inhibits CXCR4-mediated production of IL-8 and VEGF by malignant human glioma cells.

Authors:  Yi-fang Ping; Xiao-hong Yao; Jian-hong Chen; Hong Liu; Dai-lun Chen; Xiang-dong Zhou; Ji Ming Wang; Xiu-wu Bian
Journal:  J Neurooncol       Date:  2007-04-06       Impact factor: 4.506

4.  Acidic extracellular pH promotes epithelial mesenchymal transition in Lewis lung carcinoma model.

Authors:  Atsuko Suzuki; Toyonobu Maeda; Yuh Baba; Kazuhiro Shimamura; Yasumasa Kato
Journal:  Cancer Cell Int       Date:  2014-11-30       Impact factor: 5.722
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.